About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.
More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...
Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback